Rituximab versus Ocrelizumab in Newly Diagnosed Relapsing Multiple Sclerosis. Torkildsen Ø, Brustad H K, Høgestøl E A, Alstadhaug K B, Bhan A, Flemmen H Ø, Habbestad A, Høglund RAA, LeBlanc M, Lopen P, et al. N Engl J Med. 2026 Jul 02; 395(1):44-53. PMID: 42384870. Abstract CommentRecommendBookmarkWatch